SequelSEC

OptimizeRx Corp OPRX

Services-Business Services, NEC · CIK 0001448431 · Fiscal year ends 1231

Revenue
$109.43M
Fiscal year ended 2025-12-31
Operating income
$11.69M
Fiscal year ended 2025-12-31
Free cash flow
$18.66M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$240.86MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$12.84Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income46.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue2.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

Valuation over time

46.9× earnings today, against a median of 361.1× across 3 years on record. Below its own history.

Float measuredPublic floatFloat / net income
2025-06-30$240.86M46.9×
2021-06-30$1.03B2724.5×
2018-06-30$81.73M361.1×

Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.

How this compares in its industry

Percentile among the Services-Business Services, NEC filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue0.0%0th
CapEx / revenue0.1%10th
Long-term debt / equity0.17x10th
Current ratio3.04x86th
Revenue YoY growth18.8%76th
FCF margin17.0%73th
Gross margin67.3%70th
SBC / revenue6.4%69th
Operating margin10.7%68th
Effective tax rate26.2%63th
Net margin4.7%56th

OptimizeRx Corp (OPRX) reported revenue of $109.43M and net income of $5.13M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from OptimizeRx Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Business Services, NEC.

Income

OptimizeRx Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$109.43M$92.13M$71.52M$62.45M$61.29M$43.31M$24.60M$21.21M$12.13M$7.75M
Cost of revenue$35.83M$32.75M$28.62M$23.48M$25.65M$19.21M$9.16M$9.00MUnavailableUnavailable
Gross profit$73.60M$59.38M$42.90M$38.97M$35.64M$24.11M$15.44M$12.21M$5.95M$4.34M
Operating income$11.69M-$13.71M-$26.40M-$12.29M$361.10K-$2.14M-$3.69M$180.13K-$2.13M-$1.58M
Net income$5.13M-$20.11M-$17.57M-$11.44M$378.08K-$2.21M-$3.14M$226.34K-$2.10M-$1.54M
Research & development$0$0UnavailableUnavailableUnavailable$0$1.60M$0UnavailableUnavailable
Weighted-average diluted sharesshares 19.00Mshares 18.29Mshares 17.12Mshares 17.78Mshares 17.69Mshares 14.83Mshares 13.39Mshares 11.86Mshares 9.82MUnavailable
Pretax income$6.95M-$19.38M-$25.16M-$11.44M$378.08K-$2.21M-$4.04M$226.34K-$2.10M-$1.54M
Income tax expense$1.82M$725.00K-$7.60MUnavailableUnavailableUnavailable-$897.96KUnavailableUnavailableUnavailable
Diluted EPS$0.27$-1.10$-1.03$-0.64$0.02$-0.15$-0.23$0.02$-0.21Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailable$33.49M$27.70MUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

OptimizeRx Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$23.36M$13.38M$13.85M$18.21M$84.68M$10.52M$18.85M$8.91M$5.12M$7.03M
Total assets$176.92M$171.17M$183.37M$134.65M$140.99M$60.33M$56.64M$25.05M$9.76M$11.48M
Current assets$64.72M$53.97M$54.33M$98.58M$115.11M$32.86M$27.14M$15.73M$8.81M$10.18M
Total liabilities$48.62M$54.17M$56.82M$8.54M$9.61M$10.35M$11.78M$6.60M$3.54MUnavailable
Current liabilities$21.26M$18.65M$17.88M$8.40M$9.37M$10.03M$6.11M$4.23M$3.54M$3.67M
Total equity incl. NCI$128.29M$117.00M$126.55M$126.11M$131.38M$49.97M$44.86M$18.46M$6.22M$7.81M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$37.75M$38.21M$36.25M$22.16M$24.80M$17.89M$7.42M$6.46M$3.43M$1.95M
Goodwill$70.87M$70.87M$78.36M$22.67M$14.74M$14.74M$14.74M$3.68MUnavailableUnavailable
Long-term debt$21.42M$30.82M$34.23MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

OptimizeRx Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$18.72M$4.89M-$7.24M$10.65M$726.04K-$6.31M-$1.66M$792.56K-$1.48M-$465.96K
Capital expenditures$58.00K$112.00K$87.00K$81.00K$100.32K$68.04K$87.72K$34.36K$42.24K$178.43K
Investing cash flow$68.00K-$450.00K-$25.34M-$58.18M-$486.00K-$124.72K-$10.58M-$5.69M-$42.24K-$349.54K
Financing cash flow-$8.80M-$4.91M$28.22M-$18.95M$73.92M-$1.90M$22.18M$8.69M-$390.00K-$357.42K
Net change in cash$9.98M-$472.00K-$4.36M-$66.47M$74.16M-$8.34M$9.94M$3.79M-$1.91M-$1.17M
Stock-based compensation$6.96M$11.47M$13.72M$15.75M$5.49M$3.17M$2.26M$2.52M$87.38K$175.18K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$7.52M$20.02MUnavailableUnavailableUnavailableUnavailable$390.00K$806.92K
Depreciation & amortization$4.33M$4.33M$2.40M$2.02M$1.97M$2.08M$1.28M$316.50K$324.55K$235.28K

Derived

OptimizeRx Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$18.66M$4.78M-$7.33M$10.57M$625.72K-$6.38M-$1.75M$758.19K-$1.52M-$644.40K
Gross margin67.3%64.5%60.0%62.4%58.1%55.7%62.8%57.6%49.1%56.0%
Operating margin10.7%-14.9%-36.9%-19.7%0.6%-4.9%-15.0%0.8%-17.6%-20.4%
FCF margin17.0%5.2%-10.2%16.9%1.0%-14.7%-7.1%3.6%-12.6%-8.3%
SBC / revenue6.4%12.4%19.2%25.2%9.0%Unavailable9.2%11.9%0.7%2.3%
Current ratio3.04x2.89x3.04x11.74x12.29x3.28x4.44x3.72x2.49x2.78x
Revenue YoY growth18.8%28.8%14.5%1.9%41.5%76.1%16.0%74.9%56.5%Unavailable
Net margin4.7%-21.8%-24.6%-18.3%0.6%-5.1%-12.8%1.1%-17.3%-19.9%
R&D / revenue0.0%0.0%UnavailableUnavailableUnavailableUnavailable6.5%0.0%UnavailableUnavailable
CapEx / revenue0.1%0.1%0.1%0.1%0.2%0.2%0.4%0.2%0.3%2.3%
Long-term debt / equity0.17xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate26.2%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OPRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.